Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
  • Science
      • All Events
        • Cardiovascular
        • Diabetes
        • Obesity
        • Sleep
      • Immunology
      • Neuroscience
      • Oncology
      • Diabetes
      • Immunology
      • Neuroscience
      • Obesity
      • Oncology
    • Trial Imagery
    • Investigational Drugs
    • External Link Independent Research
    • External Link Clinical Trials
  • Medical Information
  • Medical Education
  • Chat Contact Us
Lilly

You are now leaving the LillyMedical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.

Obesity Journal Publications

This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here.

For all other requests, please visit our Contact Lilly services.

Foundayo™ (orforglipron)

Full Prescribing Information

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.
Published Date: April 17, 2026
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
Published Date: September 2, 2025
Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-Peptide GLP-1 Receptor Agonist
Published Date: February 24, 2024
Orforglipron (LY3502970), A Novel, Oral Non-Peptide Glucagon-Like Peptide-1 Receptor Agonist: A Phase 1a, Blinded, Placebo-Controlled, Randomized, Single- and Multiple-Ascending-Dose Study in Healthy Participants
Published Date: June 21, 2023

Treatment with Orforglipron, an Oral Glucagon Like Peptide-1 Receptor Agonist, is Associated with Improvements of CV Risk Biomarkers in Patients with Type 2 Diabetes or Obesity Without Diabetes
Published Date: June 6, 2025
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Published Date: June 23, 2023

Orforglipron for Maintenance of Body Weight Reduction: The Double-Blind, Randomized Phase 3b ATTAIN-MAINTAIN Trial.
Published Date: May 13, 2026
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for the Treatment of Obesity in People with Type 2 Diabetes (ATTAIN-2): A Phase 3, Double-Blind, Randomised, Multicentre, Placebo-Controlled Trial.
Published Date: December 20, 2025
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Published Date: September 16, 2025

No Publication Journals

Zepbound® (tirzepatide)

Full Prescribing Information

Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
Published Date: June 24, 2025
Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes
Published Date: March 01, 2023
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Published Date: June 08, 2022

Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
Published Date: June 25, 2025
Extent of MASH resolution without worsening of fibrosis across clinically relevant subgroups in the SYNERGY-NASH phase 2 trial
Published Date: June 6, 2025
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
Published Date: June 08, 2024
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.
Published Date: May 20, 2024

Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.
Published Date: November 04, 2025
A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide.
Published Date: June 25, 2025
Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.
Published Date: June 24, 2025
Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.
Published Date: June 10, 2025
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Published Date: May 11, 2025
Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.
Published Date: May 6, 2025
Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.
Published Date: March 31, 2025
Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program
Published Date: March 12, 2025
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Published Date: February 28, 2025
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Published Date: February 25, 2025
Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials
Published Date: January 12, 2025
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-related Heart Failure with Preserved Ejection Fraction: The SUMMIT CMR Substudy
Published Date: November 20, 2024
Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity
Published Date: November 18, 2024
Effects of Tirzepatide on Circulatory Overload and End-Organ Damage in Heart Failure With Preserved Ejection Fraction and Obesity: a secondary analysis of the SUMMIT trial
Published Date: November 17, 2024
Tirzepatide for Heart Failure With Preserved Ejection Fraction and Obesity
Published Date: November 15, 2024
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Published Date: November 13, 2024
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics.
Published Date: November 12, 2024
Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.
Published Date: September 16, 2024
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
Published Date: June 21, 2024
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
Published Date: May 31, 2024
Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes
Published Date: March 29, 2024
Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial.
Published Date: March 26, 2024
Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index >/=27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.
Published Date: February 05, 2024
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
Published Date: December 11, 2023
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with overweight and obesity: SURMOUNT-1 post-hoc analysis
Published Date: November 6, 2023
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
Published Date: October 15, 2023
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial
Published Date: September 14, 2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Published Date: June 26, 2023
Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program.
Published Date: December 7, 2022
Tirzepatide Once Weekly for the Treatment of Obesity
Published Date: June 9, 2022

Attitudinal Factors Influencing Willingness to Use Anti-Obesity Medication in Adults with Obesity
Published Date: September 9, 2025
Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial
Published Date: June 12, 2025
Perspectives on Obesity Management and the Use of Anti-Obesity Medicine from US Employees and Employers: Results from the OBSERVE Study.
Published Date: April 2, 2025
Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States.
Published Date: March 7, 2025
Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database
Published Date: February 25, 2025
Understanding the Impact of Non-alcoholic Steatohepatitis with Metabolic Comorbidities on Adults: A Real-World Qualitative Study
Published Date: February 29, 2024
EXIST: EXamining rIsk of excesS adiposiTy-Machine learning to predict obesity-related complications
Published Date: August 23, 2023
Real-world primary nonadherence to antiobesity medications.
Published Date: August 23, 2023
Weight management treatment modalities in patients with overweight or obesity: A retrospective cohort study of administrative claims data
Published Date: May 31, 2023
Five-Year Morbidity and Mortality Rates in a U.S. Population with Obesity with and without Prediabetes
Published Date: May 3, 2023
The Association Between Obesity and the 5-Year Prevalence of Morbidity and Mortality Among Adults with Type 2 Diabetes.
Published Date: February 23, 2023
Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review.
Published Date: March 11, 2022
Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.
Published Date: August 24, 2021
Anti-obesity Medication Use Among Adults with Overweight and Obesity in the United States: 2015-2018.
Published Date: July 12, 2021

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap
     

    This site is intended for US Healthcare Professionals only.

    4.0.95 06/2026 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2026. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    Facebook X LinkedIn
    Lilly